Alector, Inc.: Business Overview, Financials & Competitive Analysis
Alector, Inc. scores 5/10 on the AskCyborg Cyborg Score (Mixed). Alector's innovative brain-delivery approach with differentiated technology and focus on biomarkers could drive value, but the latozinemab trial failure creates significant translational biology risks. The company's stock outlook has become unfavorable due to the failure of the INFRONT-3 trial of latozinemab to meet its primary endpoint. However, Alector has $256M.
What is Alector, Inc.'s industry? Alector, Inc. (alector.com) operates in Pharmaceutical Biotechnology - Neurodegenerative Diseases. AskCyborg classifies Alector, Inc. under Pharmaceutical Biotechnology - Neurodegenerative Diseases in its company registry.
Alector is a late-stage clinical biotechnology company developing therapies focused on counteracting the devastating progression of neurodegenerative diseases. The company combines a proprietary blood-brain barrier de...
Cyborg Score thesis
Alector's innovative brain-delivery approach with differentiated technology and focus on biomarkers could drive value, but the...
Read the full analyst-debate transcript →Get the Latest Alector, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeAlector, Inc. Overview
Pro stress-test →Alector is a late-stage clinical biotechnology company developing therapies focused on counteracting the devastating progression of neurodegenerative diseases. The company combines a proprietary blood-brain barrier delivery platform with multiple clinical-stage programs targeting unmet needs in diseases like Alzheimer's, Parkinson's, and frontotemporal dementia.
Strategic Profile
Pro stress-test →The company advances its pipeline leveraging its proprietary Alector Brain Carrier (ABC) platform, which enhances drug delivery to the brain and is designed to enable peripheral dosing adaptable across multiple drug modalities including antibodies, enzymes, and siRNA. Alector has a strategic collaboration agreement with GlaxoSmithKline for the development and commercialization of progranulin-elevating monoclonal antibodies.
Competitive Landscape
Pro stress-test →Alector faces competition from larger biotech firms which increases risks of dilution and challenges in attracting resources. The company competes in the neurodegenerative disease space against other clinical-stage biotech companies pursuing Alzheimer's, Parkinson's, and FTD therapies. Alector's ABC platform differentiation provides a competitive advantage in brain delivery mechanisms.
Industry Context
Alector, Inc. operates in Pharmaceutical Biotechnology - Neurodegenerative Diseases.
Key facts
Founded: 2013 · Headquarters: South San Francisco, California · Revenue: $69M · Market cap: $172M